Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Conditions:   Non Small Cell Lung Cancer;   Metastatic Melanoma;   Metastatic Renal Cell Carcinoma;   Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: IL-2;   Drug: Pembrolizumab;   Radiation: Radiotherapy
Sponsors:   University of California, Davis;   Merck Sharp & Dohme Corp.
Not yet recruiting

http://ift.tt/2IJmEZd